ABIVAX: Now UC me? ABX464 still unencumbered as IBD paradigm shifts | BUY Top Picks | EUR52 VS. EUR53 (+76%)
ABIVAX - BUY Top Picks | EUR52 VS. EUR53 (+76%)Now UC me? ABX464 still unencumbered as IBD paradigm shifts
UC field is thinning after BMS’ Deucravacitinib Mod.-Sev. UC failure
Re-iterate BUY and EUR 52 TP (from EUR53)
Why ABX464 is the real deal: ABX464 offers efficacy/safety of anti-TNF with convenience of a once daily oral
In Phase 2b, why did the 25mg dose shown a higher potency than 50mg ? Any unknown risk related to dosing ?
Big Pharma companies need to plug US$~15b of revenue in IBD/RA during next 10 years
What would a deal entail?
ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of novel anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.